Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01328223|
Recruitment Status : Unknown
Verified March 2011 by China Medical University Hospital.
Recruitment status was: Recruiting
First Posted : April 4, 2011
Last Update Posted : April 4, 2011
Hepatocellular carcinoma (HCC) is a common cause of cancer mortality in Asia. Most patients present with intermediate or advanced disease. Percutaneous ethanol injection, radiofrequency ablation, and transcatheter arterial chemoembolization (TACE) are not considered as a curative treatment and have achieved very limited success in eradicating large HCC. With the development of new radiotherapy (RT) technique, RT can be more safely given to patients with larger tumor burden. Thus, TACE combined with RT has been suggested for treating large HCC. Based on the results of these studies, RT could achieve a tumor response rate of 50 % to 70 %. However, it has not been definitively shown to prolong the overall or disease-free survival due to lack of a phase III clinical trial. In contrast, a retrospective clinical investigation with molecular study suggests that sublethal dose of RT promoted HCC growth outside RT field.
Two phase III trials were shown to be efficacious and well-tolerated in patients with advanced HCC. Median overall survival was significantly 2 to 3 months longer in the sorafenib group than that in the placebo. It is interesting to recognize the combined therapeutic effect of RT with sorafenib. Based on several preclinical experiments, tumor angiogenesis inhibitors seem to be synergistic with irradiation when using before RT, concurrently with RT, or after RT. Thus, the investigators design a single-arm phase II clinical trial to investigate the efficacy of combined RT with sorafenib.
The eligibility criteria are patients with unresectable HCC; good performance status; no prior radiotherapy for the liver; clinical measurable tumor; good liver function and good compliance. After entering this study, the testee will receive RT to hepatic tumor with concurrently sorafenib with a dose of 400 mg twice daily. Hepatic RT will be performed with a daily fraction size of 2.0 to 2.5 Gy to a total dose of 46 Gy to 60 Gy. After RT, maintenance sorafenib with a dose of 400 mg twice daily will be ongoing. Sorafenib will be continued until the occurrence of clinical or radiologic progression, or the occurrence of either unacceptable adverse events or death. Minimum maintenance duration of 6 months is recommended, but not mandatory.
|Condition or disease||Intervention/treatment|
|Hepatocellular Carcinoma||Radiation: sorafenib and radiotherapy for hepatocellular carcinoma|
|Study Type :||Observational|
|Estimated Enrollment :||45 participants|
|Official Title:||Phase II Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma|
|Study Start Date :||September 2010|
|Estimated Primary Completion Date :||June 2012|
|Estimated Study Completion Date :||December 2012|
Radiation: sorafenib and radiotherapy for hepatocellular carcinoma
Concurrent and maintenance sorafenib 400mg twice daily
Other Name: Combined radiotherapy and sorafenib.
- Response rate [ Time Frame: 6 months ]
- The tumor response rate will be evaluated at the 6th month after the ending of radiotherapy.
- The response rate includes complete and partial response according to the RECIST (Response Evaluation Criteria in Solid Tumors) criteria.
- Disease progression-free survival [ Time Frame: 2 years ]
Disease progression-free survival:
Patients with the evidence of clinical or radiographic progressive disease will be defined as disease progression. The average time period for the follow-up will be two years.
- Overall survival [ Time Frame: 2 years ]Participants will be followed. The average time period will be two years.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01328223
|Contact: Shang-Wen Chen, MD||886-4-2205212 ext firstname.lastname@example.org|
|Taichung, Taiwan, 404|
|Contact: Shang-Wen Chen, MD 886-4-22052121 ext 7450 email@example.com|
|Sub-Investigator: Yu-Cheng Kuo|
|Sub-Investigator: Ji-An Liang, MD|
|Tainan, Taiwan, 700|
|Contact: Li-Ching Lin, MD firstname.lastname@example.org|
|Taipei, Taiwan, 100|
|Contact: Jeng-Fong Chiou, MD;PhD email@example.com|
|Principal Investigator:||Shang-Wen Chen, MD||Department of Radiation Oncology, China Medical University Hospital|